ASX Announcements.

Date Price sens. Headline pages PDF
15/11/2021 ! Immutep announces publication of SITC 2021 posters 8 PDF
15/11/2021 ! Chinese patent Granted for Efti with PD-1 Pathway Inhibitors 2 PDF
10/11/2021   Immutep announces publication of SITC 2021 abstracts 2 PDF
10/11/2021 ! Final Phase IIb AIPAC clinical trial results for Efti in MBC 4 PDF
08/11/2021   JobKeeper Payment Notice 2 PDF
02/11/2021 ! Immutep granted Chinese Patent for eftilagimod alpha 2 PDF
29/10/2021 ! Immutep receives EMA scientific advice for Phase 3 in MBC 2 PDF
28/10/2021 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
26/10/2021   Notice of Annual General Meeting/Proxy Form 25 PDF
26/10/2021   Appendix 4G 14 PDF
26/10/2021   Annual Report to shareholders 86 PDF
26/10/2021   Annual Report filed on Form 20-F with SEC 177 PDF
12/10/2021   2021 Annual General Meeting and Key Dates 2 PDF
07/10/2021   Ceasing to be a substantial holder from AEF 4 PDF
04/10/2021   Change of Director's Interest Notice - Mr Chamberlain 3 PDF
04/10/2021   Change of Director's Interest Notice - Mr Meyers 3 PDF
04/10/2021   Immutep to present Phase II TACTI-002 data at SITC 2021 3 PDF
01/10/2021   Notification regarding unquoted securities - IMM 6 PDF
01/10/2021   Application for quotation of securities - IMM 6 PDF
29/09/2021 ! Immutep Receives A$3.4 million R&D French Tax Incentive 2 PDF
28/09/2021   Immutep to Present at Healthcare Investor Conferences 1 PDF
27/09/2021   Immutep Corporate Presentation 46 PDF
21/09/2021   Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021 2 PDF
01/09/2021 ! Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 3 PDF
31/08/2021 ! Immutep's Partner, EOC Pharma, Expands Efti Trial Pipeline 2 PDF
30/08/2021 ! Appendix 4E & 2021 Full Year Statutory Accounts 86 PDF
27/08/2021 ! Chinese patent granted for anti-LAG-3 antibody LAG525 2 PDF
05/08/2021 ! INSIGHT-003 investigator-initiated trial - 1st patient dosed 2 PDF
03/08/2021   Becoming a substantial holder 3 PDF
03/08/2021   Change in substantial holding 6 PDF
30/07/2021   Cleansing Notice 1 PDF
30/07/2021 ! Completion of Placement - Tranche 2 2 PDF
29/07/2021   Application for quotation of securities - IMM 5 PDF
27/07/2021   Change in substantial holding 6 PDF
27/07/2021   Proposed issue of securities - IMM 5 PDF
26/07/2021   Results of EGM 2 PDF
26/07/2021   Chairman's EGM Address 2 PDF
26/07/2021   2021 EGM Presentation 24 PDF
23/07/2021   Application for quotation of securities - IMM 6 PDF
23/07/2021   Change in substantial holding 6 PDF
21/07/2021   Completion of Share Purchase Plan 2 PDF
15/07/2021   EGM - Now to be Held as an Online Virtual Meeting 2 PDF
13/07/2021 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
06/07/2021 ! US FDA & IRB approves start of ph2b head & neck cancer trial 2 PDF
05/07/2021   Proposed issue of securities - IMM 7 PDF
30/06/2021   Change in substantial holding from AEF 4 PDF
30/06/2021   Change in substantial holding 6 PDF
28/06/2021   Cleansing Notice 1 PDF
25/06/2021   Notice of Extraordinary General Meeting/Proxy Form 12 PDF
25/06/2021   Share Purchase Plan Offer Documents 15 PDF
25/06/2021   Application for quotation of securities - IMM 5 PDF
21/06/2021 ! Efti to be evaluated in new triple combination therapy trial 2 PDF
21/06/2021   Proposed issue of securities - IMM 5 PDF
21/06/2021 ! Immutep Capital Raising Presentation 61 PDF
21/06/2021 ! Immutep secures commitments for A$60 million in a Placement 4 PDF
17/06/2021 ! Trading Halt 2 PDF
15/06/2021   Change in substantial holding 6 PDF
08/06/2021   Appendix 2A 6 PDF
08/06/2021 ! Immutep Reveals a New anti-LAG-3 Research Program 2 PDF
07/06/2021   Application for quotation of securities - IMM 6 PDF
04/06/2021   Immutep Presentation for Jefferies Healthcare Conference 33 PDF
04/06/2021 ! Immutep Reports Positive Data from its TACTI-002 Ph 2 trial 5 PDF
04/06/2021 ! Immutep Reports Positive Final Data from INSIGHT-004 trial 3 PDF
02/06/2021 ! Immutep Granted European Patent for its LAG-3 Candidate Efti 2 PDF
01/06/2021 ! Immutep Enters New Collaboration with Merck KGaA for Efti 2 PDF
26/05/2021 ! Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination 2 PDF
25/05/2021   Immutep to Present at Jefferies Healthcare Conference 1 PDF
20/05/2021   TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 2 PDF
20/05/2021   Change in substantial holding 6 PDF
18/05/2021   Change in substantial holding 6 PDF
14/05/2021   Appendix 2A 16 PDF
13/05/2021   Immutep Corporate Presentation 48 PDF
07/05/2021 ! Operational Update 3 PDF
29/04/2021 ! TACTI-002 & INSIGHT-004 data to be presented at ASCO 2 PDF
19/04/2021 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
16/04/2021 ! Immutep Receives A$1,155,055 R&D Tax Incentive 1 PDF
14/04/2021   Immutep Investor Update 20 PDF
08/04/2021 ! Immutep Achieves Fast Track Designation for Efti from US FDA 2 PDF
07/04/2021 ! Immutep Announces European Patent Grant For LAG525 2 PDF
01/04/2021   Change in substantial holding 6 PDF
18/03/2021   Appendix 2A 16 PDF
16/03/2021 ! Immutep Collaborates with MSD for Phase IIB Head & Neck Trial 2 PDF
12/03/2021 ! S&P DJI Announces March 2021 Quarterly Rebalance 9 PDF
09/03/2021 ! Immutep Secures Second US Patent Grant for Eftilagimod Alpha 2 PDF
05/03/2021 ! Immutep Expands Part B of TACTI-002 Collaboration Trial 2 PDF
23/02/2021 ! Half Yearly Report and Accounts 30 PDF
02/02/2021   Immutep Corporate Presentation 45 PDF
27/01/2021 ! IMM - Phase II Study for Eftilagimod Alpha in COVID-19 advances 2 PDF
22/01/2021 ! Immutep Quarterly Activities Report & Appendix 4C 10 PDF
22/01/2021 ! Ulcerative Colitis Phase II Study of GSK2831781 Discontinued 2 PDF
07/01/2021 ! Recruitment of Head & Neck Cancer Patients Completed for Ph2 2 PDF
04/01/2021   Resignation and Appointment of Joint Company Secretary 1 PDF
04/01/2021   Change in substantial holding 10 PDF
31/12/2020   Appendix 2A 16 PDF
31/12/2020   Change in substantial holding 6 PDF
30/12/2020   Change in substantial holding 8 PDF
30/12/2020 ! Immutep granted US patent for Eftilagimod alpha with a PD-1 2 PDF
29/12/2020   Change in substantial holding 8 PDF
24/12/2020   Change of Director's Interest Notice - Dr Howard 3 PDF
24/12/2020   Appendix 2A 16 PDF
24/12/2020   Becoming a substantial holder 9 PDF
18/12/2020   Change in substantial holding 6 PDF
17/12/2020   Change in substantial holding 6 PDF
16/12/2020 ! Immutep Upscales Efti Manufacturing 2 PDF
16/12/2020   Change in substantial holding 6 PDF
15/12/2020 ! Operational Update 2 PDF
15/12/2020   Ceasing to be a substantial holder 1 PDF
15/12/2020   Change in substantial holding 6 PDF
11/12/2020   Appendix 2A 16 PDF
10/12/2020 ! Immutep's partner EOC Pharma to start Ph II trial in MBC 2 PDF
10/12/2020 ! Overall Survival Data from Ph IIb AIPAC Breast Cancer trial 4 PDF
27/11/2020   Change in substantial holding 6 PDF
25/11/2020   Cleansing Notice 1 PDF
24/11/2020   Change of substantial holding from AEF 4 PDF
24/11/2020   Appendix 2A 16 PDF
19/11/2020 ! Proposed issue of Securities - IMM 5 PDF
19/11/2020   Immutep Investor Presentation 52 PDF
19/11/2020 ! Immutep completes a A$29.6 million placement 3 PDF
19/11/2020 ! Immutep expands TACTI-002 Collaboration Trial with MSD 3 PDF
18/11/2020   Change in substantial holding 6 PDF
17/11/2020 ! Trading Halt 2 PDF
17/11/2020 ! Pause in Trading 1 PDF
10/11/2020 ! Encouraging Phase II TACTI-002 Data Reported at SITC 2020 5 PDF
09/11/2020 ! Immutep Announces Australian Patent Grant for IMP701 2 PDF
06/11/2020   Change of Director's Interest Note - Grant Chamberlain 3 PDF
06/11/2020   Appendix 3G 15 PDF
06/11/2020   Proposed issue of Securities - IMM 5 PDF
03/11/2020   Immutep to present TACTI-002 phase 2 data at SITC 2020 2 PDF
02/11/2020   Lapse of Unlisted Options 1 PDF
30/10/2020 ! Immutep enters into a Licence & Collaboration with LabCorp 2 PDF
27/10/2020   Results of Meeting 2 PDF
27/10/2020   Immutep AGM 2020 - Chairman's Address 3 PDF
27/10/2020 ! Immutep AGM 2020 - CEO Marc Voigt's Presentation 21 PDF
23/10/2020 ! COVID-19 phase 2 investigator initiated trial commences 4 PDF
22/10/2020 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
21/10/2020 ! Immutep granted European patent for IMP761 2 PDF
19/10/2020   Immutep to present AIPAC Overall Survival data at SABCS 2020 2 PDF
06/10/2020   Change in substantial holding 6 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Chamberlain 3 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Meyers 3 PDF
05/10/2020   Appendix 3Y - Change of Director's Interest Notice - Mr Voigt 3 PDF
02/10/2020   Appendix 2A 17 PDF
02/10/2020   Appendix 3G 15 PDF
28/09/2020   Annual Report filed on Form 20-F with SEC 137 PDF
25/09/2020   Notice of Annual General Meeting/Proxy Form 28 PDF
25/09/2020   Appendix 4G & Corporate Governance Statement 35 PDF
25/09/2020   Annual Report to shareholders 87 PDF
18/09/2020 ! Immutep reports improving results from INSIGHT-004 trial 3 PDF
18/09/2020 ! Improving results from stage 1 of TACTI-002 Ph II  trial 4 PDF
14/09/2020   Change in substantial holding 6 PDF
11/09/2020   2020 Annual General Meeting and Key Dates 2 PDF
31/08/2020 ! IMM and Monash Uni receive funding grant for LAG-3 Research 2 PDF
26/08/2020   New data to be presented at ESMO for eftilagimod alpha 3 PDF
25/08/2020 ! Appendix 4E & 2020 Full Year Statutory Accounts 85 PDF
18/08/2020 ! Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study 2 PDF
17/08/2020   Immutep Investor Update 14 PDF
11/08/2020 ! Immutep Granted US Patent for Eftilagimod Alpha 2 PDF
11/08/2020   Lapse of Unlisted Options 1 PDF
27/07/2020   Change in substantial holding 6 PDF
23/07/2020 ! Immutep Quarterly Activities Report & Appendix 4C 9 PDF
21/07/2020   Change in substantial holding 6 PDF
15/07/2020 ! Immutep Announces United States Patent Grant for IMP701 Antibody 2 PDF
29/06/2020 ! Immutep Completes Recruitment for Part A of TACTI-002 trial 3 PDF
22/06/2020 ! Immutep receives A$1,437,826 R&D Tax Incentive 2 PDF
01/06/2020 ! Immutep announces improving data from TACT I - 002 ph II trial 4 PDF
01/06/2020 ! Immutep Reports First Result from INSIGHT - 004 Study 3 PDF
29/05/2020 ! Immutep Receives $3.6M R&D French Tax Incentive 2 PDF
27/05/2020   Immutep webcast to present new data from 2020 ASCO meeting 2 PDF
07/05/2020   Becoming a substantial holder from AEF 4 PDF
07/05/2020 ! Immutep Granted Japanese Patent for Eftilagimod Alpha 2 PDF
07/05/2020   Change in substantial holding 6 PDF
05/05/2020   Cleansing Notice 1 PDF
04/05/2020   Appendix 2A 16 PDF
01/05/2020   Immutep presents at NWR Virtual Small Cap Health Conference 1 PDF
30/04/2020 ! INSIGHT-004 and TACTI-002 data to be presented at ASCO 2 PDF
29/04/2020 ! Proposed issue of Securities - IMM 5 PDF
29/04/2020   Immutep Investor Presentation 51 PDF
29/04/2020 ! Immutep completes A$12 million placement 3 PDF
28/04/2020 ! Immutep Reports Positive Phase II TACTI-002 Data 5 PDF
27/04/2020 ! Trading Halt 2 PDF
22/04/2020   Enrollment completed for the INSIGHT-004 Study 3 PDF
20/04/2020 ! Immutep March Quarterly Activities Report & Appendix 4C 10 PDF
16/04/2020 !
Immutep advances its LAG-3 agonist for autoimmune diseases
 2 PDF
14/04/2020 !
Immutep presents TACTI-002 data at AACR Virtual Meeting
 2 PDF
08/04/2020 !
EOC Pharma confirms plans to advance Efti in China for MBC
 2 PDF
26/03/2020 !
Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
 20 PDF
25/03/2020 !
Immutep reports supportive efficacy data from AIPAC study
 4 PDF
20/03/2020  
Immutep's Partner, EOC completes recruitment of Phase 1
 3 PDF
16/03/2020  
Change of Director's Interest Notice - Mr Chamberlain
 2 PDF
09/03/2020   Immutep receives 2nd IND approval for efti from US FDA 2 PDF
02/03/2020   Change in substantial holding 6 PDF
25/02/2020   Immutep Clinical Update & Results Global Webcast Slides 23 PDF
21/02/2020   Change in substantial holding 6 PDF
21/02/2020 ! Half Yearly Report and Accounts 30 PDF
19/02/2020 ! Immutep reports positive TACTI-002 data 5 PDF
05/02/2020   Change in substantial holding 6 PDF
04/02/2020   Immutep to present TACTI-002 data at German Cancer Congress 2 PDF
29/01/2020 ! Immutep Activities Report 4 PDF
29/01/2020 ! Appendix 4C - Quarterly 5 PDF
10/01/2020   Immutep Corporate Presentation 33 PDF
09/01/2020 ! Immutep expands Part C of TACTI-002 due to positive data 2 PDF
06/01/2020   Change in substantial holding 6 PDF
02/01/2020   Change of Director's Interest Notice 3 PDF
02/01/2020   Appendix 3B 15 PDF
19/12/2019 ! INSIGHT-004 clinical trial update 3 PDF
09/12/2019   Change of Director's Interest Notice - Mr Meyers 3 PDF
09/12/2019   Change of Director's Interest Notice - Dr Howard 2 PDF
09/12/2019   Change of Director's Interest Notice - Mr Voigt 3 PDF
02/12/2019   Appendix 3B 16 PDF
22/11/2019   Immutep Investor Update 13 PDF
14/11/2019 ! Immutep announces European patent grant for LAG525 antibody 2 PDF
08/11/2019 ! IMM presents positive interim phase 2 TACTI-002 data at SITC 3 PDF
01/11/2019   Update - Consolidation Split - IMM 4 PDF
01/11/2019   2019 AGM CEO Presentation 24 PDF
01/11/2019   2019 AGM Chairman's Address 3 PDF
01/11/2019   Results of Annual General Meeting 2 PDF
31/10/2019   Consolidation/Split - IMM 4 PDF
28/10/2019 ! Operational Update 3 PDF
24/10/2019   Change in substantial holding 6 PDF
23/10/2019 ! Appendix 4C - quarterly 5 PDF
15/10/2019 ! Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial
in Melanoma		 23 PDF
10/10/2019 ! Immutep receives A$2.5M R&D French Tax Incentive 2 PDF
10/10/2019   Immutep to present data at upcoming Industry Conferences 2 PDF
04/10/2019   Change of Director's Interest Notice - Mr Chamberlain 3 PDF
04/10/2019   Change of Director's Interest Notice - Mr Meyers 3 PDF
03/10/2019   Appendix 3B 15 PDF
30/09/2019   Immutep Investor Presentation 39 PDF
30/09/2019   Notice of Annual General Meeting/Proxy Form 31 PDF
30/09/2019   Annual Report to shareholders 82 PDF
30/09/2019   Appendix 4G & Corporate Governance Statement 32 PDF
26/09/2019 ! Immutep expands Part A of TACTI-002 due to positive data 3 PDF
24/09/2019   Annual Report filed on Form 20-F with SEC 199 PDF
23/09/2019 ! Immutep to receive GBP4M Milestone Payment from GSK 2 PDF
17/09/2019 ! Japanese patent granted for LAG525 antibody 2 PDF
22/08/2019 ! Immutep granted European patent for IMP321 in cancer 2 PDF
20/08/2019 ! Appendix 4E & 2019 Full Year Statutory Accounts 83 PDF
13/08/2019   Ceasing to be a substantial holder from AEF 3 PDF
09/08/2019   Change in substantial holding 5 PDF
07/08/2019   Change of Director's Interest Notice - Mr Chamberlain 2 PDF
07/08/2019   Change of Director's Interest Notice - Mr Voigt 2 PDF
06/08/2019   Immutep completes fully underwritten A$6M Entitlement Offer 2 PDF
01/08/2019 ! Entitlement Offer Results & Shortfall Notification 2 PDF
26/07/2019 ! Operational Update 4 PDF
26/07/2019 ! Appendix 4C - quarterly 5 PDF
19/07/2019   Becoming a substantial holder from AEF 3 PDF
19/07/2019   Change in substantial holding 6 PDF
17/07/2019   Mailing of Offer Booklet for Entitlement Offer 1 PDF
17/07/2019   Cleansing Notice 1 PDF
17/07/2019  
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
 1 PDF
09/07/2019  
Cleansing Notice
 1 PDF
09/07/2019  
Letter to Ineligible Shareholders
 2 PDF
09/07/2019  
Letter to Eligible Shareholders
 3 PDF
09/07/2019  
Appendix 3B
 14 PDF
09/07/2019 !
Immutep Entitlement Offer Booklet
 56 PDF
09/07/2019 !
Immutep Capital Raising Presentation
 27 PDF
09/07/2019 !
Immutep raises A$10M via placement & entitlement offer
 4 PDF
05/07/2019 !
Trading Halt
 2 PDF
25/06/2019 !
Immutep completes recruitment of AIPAC trial in MBC
 3 PDF
25/06/2019  
Immutep hosts Key Opinion Leader Call
 2 PDF
21/06/2019 !
Immutep granted Australian patent for eftilagimod alpha
 2 PDF
13/06/2019 !
Immutep completes recruitment of initial NSCLC cohort
 2 PDF
06/06/2019 !
First patient dosed in INSIGHT-004
 3 PDF
03/06/2019  
Appendix 3B
 14 PDF
03/06/2019  
Immutep Poster Presentation at ASCO
 3 PDF
23/05/2019 !
Immutep granted European patent for eftilagimod alpha
 2 PDF
17/05/2019 !
More mature positive data for TACTI-mel trial presented
 2 PDF
10/05/2019  
Immutep to present at upcoming industry conferences
 2 PDF
08/05/2019  
Becoming a substantial holder
 67 PDF
30/04/2019 !
Operational Update
 4 PDF
24/04/2019 !
Appendix 4C - quarterly
 5 PDF
02/04/2019  
Webcast slides for eftilagimod alpha (IMP321)
 29 PDF
27/03/2019  
Webcast details for update on eftilagimod alpha (IMP321)
 2 PDF
26/03/2019  
Ceasing to be a substantial holder
 10 PDF
25/03/2019  
IMP761 Webcast Slides
 13 PDF
22/03/2019 !
Immutep granted US patent for IMP321
 2 PDF
19/03/2019  
Webcast to discuss IMP761 preclinical results
 2 PDF
08/03/2019 !
IMP761 results presented at ECCO conference
 2 PDF
07/03/2019 !
Immutep receives A$872,351 R&D Tax Incentive
 1 PDF
06/03/2019 !
Immutep doses First Patient in TACTI-002 Phase II Trial
 4 PDF
06/03/2019 !
TACTI-mel data presented at World Immunotherapy Congress
 3 PDF
04/03/2019  
Immutep to present at Oppenheimer Healthcare Conference
 2 PDF
27/02/2019  
Half Year Accounts
 29 PDF
26/02/2019  
Immutep to present at upcoming industry conferences
 2 PDF
25/02/2019  
Immutep Presentation to Emergence Conference
 18 PDF
31/01/2019  
Immutep Investor Update
 14 PDF
24/01/2019 !
Appendix 4C - quarterly
 5 PDF
07/01/2019 !
Immutep enters into collaboration with CYTLIMIC
 3 PDF
04/01/2019  
Change of Director's Interest Notice - Dr Howard
 3 PDF
04/01/2019  
Change of Director's Interest Notice - Mr Voigt
 4 PDF
02/01/2019  
Appendix 3B
  15 PDF
24/12/2018   Becoming a substantial holder 4 PDF
21/12/2018   Disclosure Under LR 3.10.5A and 7.1A.4(b) 2 PDF
21/12/2018   Cleansing Notice 1 PDF
21/12/2018   Appendix 3B 14 PDF
20/12/2018 ! Cleansing prospectus for issue of warrants 46 PDF
19/12/2018 ! Immutep announces US$5.2 million capital raising 3 PDF
29/11/2018 ! European patent granted for IMP321 & antibody combinations 2 PDF
28/11/2018 ! Immutep granted European patent for IMP321 2 PDF
27/11/2018 ! Immutep presents new TACTI-mel data at ICI Europe Summit 3 PDF
26/11/2018   Change of Director's Interest Notice - Dr Howard 2 PDF
21/11/2018   Appendix 3B 14 PDF
16/11/2018   Results of Meeting 3 PDF
16/11/2018   2018 AGM CEO Presentation 23 PDF
16/11/2018   2018 AGM Chairman's Address 3 PDF
12/11/2018 ! Positive interim TACTI-mel data presented at SITC 3 PDF
01/11/2018 ! Operational Update 4 PDF
30/10/2018   AusBiotech Invest presentation slides 11 PDF
25/10/2018 ! Appendix 4C - quarterly 5 PDF
22/10/2018   Annual Report filed on Form 20-F with SEC 127 PDF
11/10/2018   Notice of Annual General Meeting/Proxy Form 27 PDF
11/10/2018   Annual Report to shareholders 80 PDF
11/10/2018   Appendix 4G & Corporate Governance Statement 32 PDF
04/10/2018   Appendix 3B & cleansing notice 15 PDF
02/10/2018   Change of Director's Interest Notice - Mr Chamberlain 3 PDF
02/10/2018   Change of Director's Interest Notice - Mr Meyers 3 PDF
02/10/2018   Appendix 3B & cleansing notice 15 PDF
02/10/2018   Ceasing to be a substantial holder from AEF 3 PDF
02/10/2018   Immutep to present at SITC 2018 2 PDF
28/09/2018   Appendix 3B & cleansing notice 14 PDF
27/09/2018   Appendix 3B & cleansing notice 14 PDF
27/09/2018   Change in substantial holding from AEF 3 PDF
26/09/2018   Immutep to present at Ladenburg Thalmann conference 1 PDF
24/09/2018 ! Immutep enters into collaboration with Pfizer & Merck KGaA 4 PDF
07/09/2018   Immutep presentation for BioCentury NewsMakers conference 29 PDF
03/09/2018   Change in substantial holding from AEF 3 PDF
03/09/2018 ! Progress towards clinical development of IMP761 2 PDF
21/08/2018 ! Appendix 4E & 2018 Full Year Statutory Accounts 82 PDF
21/08/2018 ! Immutep receives A$1.9M from French R&D tax cash rebate 2 PDF
16/08/2018   Immutep to present at BioCentury NewsMakers conference 2 PDF
07/08/2018 ! Immutep secures Canadian patent grant for IMP731 antibody 2 PDF
07/08/2018 ! TACTI-mel Patient Recruitment Complete & Operational Update 3 PDF
31/07/2018 ! Immutep receives IND approval from US FDA for IMP321 2 PDF
30/07/2018 ! Appendix 4C - quarterly 5 PDF
02/07/2018 ! Immutep submits IND application with FDA 2 PDF
19/06/2018   Investor Update 13 PDF
19/06/2018 ! Mid-point of patient enrolment reached in AIPAC trial 2 PDF
04/06/2018   Immutep Poster Presentations at ASCO 2 PDF
30/05/2018 ! Webcast slides for TACTI-mel clinical trial data 25 PDF
30/05/2018 ! New Data from Ongoing TACTI-mel Study 2 PDF
25/05/2018   3rd Annual Advances in Immuno-Oncology Congress Presentation 37 PDF
17/05/2018   Webcast to discuss interim results from TACTI-mel 3 PDF
15/05/2018   Response to ASX Price Query 3 PDF
04/05/2018   Immutep to present at ASCO 2 PDF
23/04/2018   Appendix 4C 5 PDF
13/04/2018   Appendix 3B 13 PDF
13/04/2018   Completion of Share Purchase Plan 2 PDF
03/04/2018 ! Operational Update 2 PDF

 

Financial reports.